RxDoctor Payments Data

Joseph Messina, MD

Internal Medicine · Grenada, MSNPI 1518980887

Payments from drug & device makers

$2,724in general payments, 2019–2025

Across 163 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$516
  • Novo Nordisk$369
  • Pfizer$318
  • AbbVie$283
  • Amgen$257
  • Boehringer Ingelheim$185
  • plus $797 from 15 others

What the payments were for

  • Food & beverage$2,63497%
  • Education$903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,724 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$97,213
Medicare patients
936
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol135$91,670
EliquisApixaban100$72,813
OzempicSemaglutide77$67,640
JardianceEmpagliflozin86$64,598
MounjaroTirzepatide56$54,061
XareltoRivaroxaban51$37,595
JanuviaSitagliptin Phosphate44$36,485
LinzessLinaclotide37$25,411
Tresiba Flextouch U-100Insulin Degludec30$17,698
VraylarCariprazine Hcl11$17,363
Repatha SureclickEvolocumab22$14,960
TradjentaLinagliptin18$14,743
RybelsusSemaglutide12$12,958
AbrysvoRsv Vacc, Pref A And Pref B/Pf38$11,466
ShingrixVaricella-Zoster Ge/As01b/Pf39$8,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$516$91,670135 claims
PfizerEliquis, Abrysvo$318$84,279138 claims
Novo NordiskOzempic, Rybelsus$369$80,59989 claims
Boehringer IngelheimJardiance, Tradjenta$185$79,341104 claims
Lilly USA, LLCMounjaro$179$54,06156 claims
AbbVieLinzess, Vraylar, Synthroid$283$47,565112 claims
Johnson & JohnsonXarelto$141$37,59551 claims
GSKShingrix, Trelegy Ellipta, Anoro Ellipta$21$20,04562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Grenada

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →